List of Actively Accruing Cancer Clinical Trials. DST Study Protocol acronym Project Title Site status detail Clinical trials gov number

Transcription

1 Breast ALTENS(Hot Flash Study) Hot Flash Study A Phase II Study of Acupuncture-like trancutaneous electrical nerve stimulation in the management of vasomotor symptoms induced by breast cancer treatments. Breast Cardiac Biomarker (Cabot) CABOT Determining the Cardiac Biomarker Profile in Breast Cancer Patients Receiving Adjuvant Trastuzumab Therapy Breast IND.197 A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer (IND197) Breast LEGACY Establishment of a cohort of girls in breast cancer families The Ontario LEGACY Pilot Breast MA.33 A Randomised Phase III Study Of Radiation Doses And Fractionation Schedules For Ductal Carcinoma In Situ (Dcis) Of The Breast Breast MA.34 (BIG 4-11 / BO25126 / TOC4939g) Aphinity A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer Breast MAC.15 (S1007) A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor- Positive and Her2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less NCT NCT NCT NCT Page 1 of 11

2 Breast OCOG-2010-IMPACT IMPACT A Pilot Study of Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy NCT Breast Once-A-Day Partial OPAR 5D CRT randomized to 27.5 vs 30 GY Breast Irradiation(OPAR) Breast ONCOTYPE DX A Prospective Cohort Study to Evaluate the Oncotype DX Test in Early Stage Breast Cancer GI CO.21 CHALLENGE A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE) NCT NCT GI CP Imclone An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With IMC 1121B or IMC 18F1 or Without Investigational Therapy as Second Line Therapy in Patients With Metastatic Colorectal Cancer Following Disease Progression on First Line Irinotecan-based Therapy NCT Page 2 of 11

3 GI CRC.6 A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer GI JX594-CRC019 A Phase 1/2a Dose-escalation Study of JX- 594 (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Followed by Intratumoral (IT) Boosts Alone and in Combination with Irinotecan in Patients with Metastatic, Refractory Colorectal Carcinoma. NCT NCT GI PA.6 (PRODIGE) Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mfolfirinox) in Patients With Resected Pancreatic Adenocarcinoma NCT GU\RENAL 9785-CL-0401 MDV 3100 EAP Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel- Based Chemotherapy NCT GU\RENAL AV A Rollover Protocol to Allow Continued Access to Tivozanib (AV-951) for Subjects Enrolled in Other Tivozanib Protocols NCT Page 3 of 11

4 GU\RENAL CFG920X2101 A phase I/II, multicenter, open-label dose finding study of oral CFG920 in patients with metastatic castration-resistant prostate cancer GU\RENAL IMRT_ISD_JARES Randomized Study of Quality of Life in Patients with High-Risk Prostate Cancer Undergoing Radiotherapy: Role of Pelvic Nodal IMRT GU\RENAL IND.205 A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer GU\RENAL MUC1 MUC1/CAN-ON- 001 A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1 GU\RENAL OGX AFFINITY A randomized phase 3 study comparing cabazitaxel/prednisone in combination with custirsen (OGX-011) to cabazitaxel/prednisone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer GU\RENAL OGX A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients with Advanced Transitional Cell Carcinoma GU\RENAL OZM-042 A Phase II, Multi-Centre, Study of the Efficacy and Safety of Sunitinib Given on an Individualized Schedule as First-Line Therapy for Metastatic Renal Cell Cancer. NCT NCT NCT NCT NCT NCT Page 4 of 11

5 GU\RENAL PR.13 PR.13(Arm A) Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS) NCT GU\RENAL RTOG 0534:Phase III PELVIC Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer NCT GU\RENAL RTOG 0938:Phase II Hypofractionated RT for prostate A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer GU\RENAL VEG113387(PROTECT) PROTECT A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT) GYNE CBKM120C2201 A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma GYNE CX.5 (SHAPE) SHAPE Radical Versus Simple Hysterectomy and Pelvic Node Dissection in Patients With Early Stage Cervical Cancer GYNE INCB A Phase 2 Study of the IDO Inhibitor INCB Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy On hold NCT NCT NCT CT NCT Page 5 of 11

6 GYNE MK A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK ) GYNE MM A Phase II Randomized Open Label Study of MM-121 in combination with Paclitaxel versus Paclitaxel alone in patients with Platinum Resistant/ Refractory Advanced Ovarian Cancers GYNE PET LACE The Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer Head&Neck DOVE A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE) Head&Neck REO 018 Efficacy Study of REOLYSIN in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers Head&Neck RTOG 0631:Phase II/III Radiosurg for spine METs Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis Head&Neck T2 Larynx Phase I Study of Tolerance of Localized Glottic (T2 N0) Cancer treated with Dose Escalated Intensity Modulated Radiation Therapy NCT NCT NCT NCT NCT NCT Page 6 of 11

7 Hematology CA Dasatinib Combo With SMO Inhibitor (BMS ) Hematology CAM0104(Accapella) Accapella Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T- Cell Lymphomas (ACCAPELA) Hematology IND.194 A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma Hematology NCRN188 - RESPONSE CINC424B2301(RE SPONSE) Randomized, open label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK inhibitor INC424 tablets versus best available care (The RESPONSE Trial) NCT NCT NCT NCT Hematology PCI-32765CLL3001 (HELIOS) PCI-32765CLL3001 Randomized, Double-blind, Placebocontrolled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (The HELIOS trial). NCT Hematology PHL-074 A Phase I/II study of azacitidine combined with mitoxantrone and etoposide (ANOVE) chemotherapy for patients age > 60 with poor prognosis acute myeloid leukemia (AML). NCT Page 7 of 11

8 Lung BR.26 PF in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer Lung CA A Multi-arm Phase I study of BMS in combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, or Carboplatin/Paclitaxel in subjects with Chemotherapy-Naive Stage IIIB/IV Nonsmall Cell Lung Cancer (NSCLC) Lung CONVERT BR.28 A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status Lung EMR Collect Long-term Data on Subjects Following Participation in Previous EMD (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials Lung IMGN IMGN901 A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine (IMGN901) in Combination with Carboplatin/Etoposide in Patients with Advanced Solid Tumors including Extensive Stage Small Cell Lung Cancer NCT NCT NCT NCT Page 8 of 11

9 Lung IND.207 A Phase II Study of PF in Patients With Advanced Malignant Pleural Mesothelioma Lung OCOG-2011-BRACHY Brachy A Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy (BRACHY) Lung STA Galaxy Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Lung STA A Single Arm, Phase 2 Study of Ganetespib in Subjects with Advanced Non-Small-Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC) NCT NCT NCT NCT Lung TIDAL Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non- Small Cell Lung Cancer (TIDAL) Melanoma MEK A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subjects with unresectable (Stage IIIc) or metastatic (Stage IV) BRAF V600E/K mutation-positive cutaneous melanoma. NCT NCT Neuro CBKM120E2101 A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma NCT Page 9 of 11

10 Neuro CDX (ACT IV) ACT IV An International, Randomized, Double- Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIIIpositive Glioblastoma (The ACT IV Study) Neuro CE.6 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Neuro CEC.3/N107C A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease NCT NCT NCT Neuro GO27819 Phase II Study of MetMAb in Patients with Recurrent Glioblastoma G GO27819 a randomized, double-blind, placebo-controlled, multicenter phase ii study evaluating the efficacy and safety of onartuzumab in combination with bevacizumab or onartuzumab monotherapy in patients with recurrent glioblastoma NCT Neuro JNG-001 TRICK A Randomized Trial of Robotic Compared to Fixed Gantry Radiosurgery for Brain Metastases. Neuro N0574(RTOG 0671) Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Other IND.206 A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours NCT NCT NCT Page 10 of 11

11 Other PROUD Study (PAL-ABST- PROUD/Abstral 401) Program Abstral Drug Utilization Study - Observational Study Evaluating "Real World" Utilization of Abstral in Canada Phase I TGWS-001 Feasibility Clinical Study of Targeted and Genome-Wide Sequencing Phase I NP27872 A multi-center, open-label, first-in-human, phase I dose-escalation study of single agent RO , a small molecule MDM2 antagonist, administered orally in patients with advanced malignancies, except leukemia Phase I PJC-008 A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors with an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumor Phase I SOR-C13 01 A Phase I, Open-Label, Dose Escalation Study To Assess Safety and Tolerability of Sor-C13 in Subjects with Advanced Solid Tumors Commonly Known to Express The Trpv6 Ion Channel Sarcoma SR.6 SARC021 A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma On hold NCT NCT NCT NCT NCT * You can search the trial details by putting the clnical trial gov number in the website: or search for key words at Updated Feb.6, 2013 Page 11 of 11